Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Risk Assessment

View and export this data going back to 2003. Start your Free Trial

What is Zhejiang Huahai Pharmaceutical Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Zhejiang Huahai Pharmaceutical Co is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Zhejiang Huahai Pharmaceutical Co's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Huahai Pharmaceutical Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhejiang Huahai Pharmaceutical Co's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Huahai Pharmaceutical Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Zhejiang Huahai Pharmaceutical Co's Risk Assessment falls into.

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Zhejiang Huahai Pharmaceutical Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Zhejiang Huahai Pharmaceutical Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Huahai Pharmaceutical Co Ltd (SHSE:600521) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

Economic Development Zone, Xunqiao Town, Linhai, Taizhou, Zhejiang, CHN, 317024

Website

http://www.huahaipharm.com

Zhejiang Huahai Pharmaceutical Co Ltd provides formulations, active pharmaceutical ingredients, and intermediates in China and internationally. The company also offers pril products, including captopril, enalapril, and lisinopril.

Executives

Chen Bao Hua	Director
Shang Fei	senior management
Du Jun	Director
Su Yan	Director
Chen Dun Yuan	senior management
Li Hong	Director
Guo Si Jia	senior management
Li Min	senior management
Xu Bo	senior management
Wang Jie	senior management
Chen Qi Mao	senior management
Zhang Hong	senior management
Zhang Mei	senior management
Zhu Yong Hua	Directors, senior managers
Wang Yi Hua	senior management

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Headlines

No Headlines